https://www.selleckchem.com/products/tmp195.html
Breast cancer (BC) patients with T1N0 tumors have relatively favorable clinical outcomes. However, it remains unclear whether molecular subtypes can aide in prognostic prediction for such small, nodal-negative BC cases and guide decision-making about escalating or de-escalating treatments. T1N0 BC patients diagnosed between 2009 and 2017 were included and classified into three subgroups according to receptor status 1) hormonal receptor (HR)+/human epidermal growth factor receptor-2 (HER2)-; 2) HER2+; and 3) triple negative (TN) (HR-/HER2
Like
Comment
Share
